Could a heart drug help immunotherapy fight breast cancer again?
NCT ID NCT05741164
First seen Feb 18, 2026 · Last updated Jun 23, 2026 · Updated 19 times
Summary
This phase 2 trial tests whether adding the beta-blocker propranolol to the immunotherapy drug pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer that has stopped responding to checkpoint inhibitors. About 37 adults with advanced, unresectable cancer will receive both drugs and be monitored for tumor response. The goal is to see if propranolol can re-sensitize the immune system to fight the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Roswell Park Cancer Institute
WITHDRAWNBuffalo, New York, 14263, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Propranolol (a beta-blocker) and pembrolizumab (an immunotherapy drug)
What this could lead to
If it works, this could offer a new treatment option for people with triple-negative breast cancer that no longer responds to standard immunotherapy.
What could go wrong
This is a small, early-phase trial with only 37 participants. It is testing a combination in a hard-to-treat cancer, so success is uncertain and benefits may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.